BACKGROUND: The purpose of this study was to evaluate the relationship between cognitive performance, risk factors for cardiovascular and cerebrovascular disease (CVD), and HIV infection in the era of highly active antiretroviral therapy. METHODS: We evaluated the cognitive functions of men enrolled in the cardiovascular disease substudy of the Multicenter AIDS Cohort Study who were aged > or =40 years, with no self-reported history of heart disease or cerebrovascular disease. Results from comprehensive neuropsychological evaluations were used to construct composite scores of psychomotor speed and memory performance. Subclinical CVD was assessed by measuring coronary artery calcium and carotid artery intima-media thickness (IMT), as well as laboratory measures, including total cholesterol, fasting glucose, glycosylated hemoglobin, glomerular filtration rate (estimated), and standardized blood pressure and heart rate measures. RESULTS: After accounting for education, depression, and race, carotid IMT and glomerular filtration rate were significantly associated with psychomotor speed, whereas IMT was associated with memory test performance. HIV serostatus was not significantly associated with poorer cognitive test performance. However, among the HIV-infected individuals, the presence of detectable HIV RNA in plasma was linked to lower memory performance. CONCLUSIONS: These findings suggest that HIV infection may not be the most important predictor of cognitive performance among older gay and bisexual men in the post-highly active antiretroviral therapy era, at least among those with access to medical care and to appropriate medications. Medical factors associated with normal aging are significantly associated with performance on neuropsychological tests, and good clinical management of these factors both in HIV-infected individuals and those at risk for infection may have beneficial effects in the short term and could reduce the risk of subsequent cognitive decline.
BACKGROUND: The purpose of this study was to evaluate the relationship between cognitive performance, risk factors for cardiovascular and cerebrovascular disease (CVD), and HIV infection in the era of highly active antiretroviral therapy. METHODS: We evaluated the cognitive functions of men enrolled in the cardiovascular disease substudy of the Multicenter AIDS Cohort Study who were aged > or =40 years, with no self-reported history of heart disease or cerebrovascular disease. Results from comprehensive neuropsychological evaluations were used to construct composite scores of psychomotor speed and memory performance. Subclinical CVD was assessed by measuring coronary artery calcium and carotid artery intima-media thickness (IMT), as well as laboratory measures, including total cholesterol, fasting glucose, glycosylated hemoglobin, glomerular filtration rate (estimated), and standardized blood pressure and heart rate measures. RESULTS: After accounting for education, depression, and race, carotid IMT and glomerular filtration rate were significantly associated with psychomotor speed, whereas IMT was associated with memory test performance. HIV serostatus was not significantly associated with poorer cognitive test performance. However, among the HIV-infected individuals, the presence of detectable HIV RNA in plasma was linked to lower memory performance. CONCLUSIONS: These findings suggest that HIV infection may not be the most important predictor of cognitive performance among older gay and bisexual men in the post-highly active antiretroviral therapy era, at least among those with access to medical care and to appropriate medications. Medical factors associated with normal aging are significantly associated with performance on neuropsychological tests, and good clinical management of these factors both in HIV-infected individuals and those at risk for infection may have beneficial effects in the short term and could reduce the risk of subsequent cognitive decline.
Authors: I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg Journal: Lancet Date: 1996-04-27 Impact factor: 79.321
Authors: Victor G Valcour; Cecilia M Shikuma; Bruce T Shiramizu; Andrew E Williams; Michael R Watters; Pamela W Poff; John S Grove; Ola A Selnes; Ned C Sacktor Journal: J Acquir Immune Defic Syndr Date: 2005-01-01 Impact factor: 3.731
Authors: V Valcour; C Shikuma; B Shiramizu; M Watters; P Poff; O A Selnes; J Grove; Y Liu; K-B Abdul-Majid; S Gartner; N Sacktor Journal: J Neuroimmunol Date: 2004-12 Impact factor: 3.478
Authors: Lawrence A Kingsley; Juliana Cuervo-Rojas; Alvaro Muñoz; Frank J Palella; Wendy Post; Mallory D Witt; Matthew Budoff; Lewis Kuller Journal: AIDS Date: 2008-08-20 Impact factor: 4.177
Authors: A Chiesi; S Vella; L G Dally; C Pedersen; S Danner; A M Johnson; S Schwander; F D Goebel; M Glauser; F Antunes Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1996-01-01
Authors: Ann B Ragin; Gypsyamber D'Souza; Sandra Reynolds; Eric Miller; Ned Sacktor; Ola A Selnes; Eileen Martin; Barbara R Visscher; James T Becker Journal: J Neurovirol Date: 2011-09-29 Impact factor: 2.643
Authors: Ned Sacktor; Richard L Skolasky; Christopher Cox; Ola Selnes; James T Becker; Bruce Cohen; Eileen Martin; Eric N Miller Journal: J Neurovirol Date: 2010-10 Impact factor: 2.643
Authors: Angela Matinella; M Lanzafame; M A Bonometti; A Gajofatto; E Concia; S Vento; S Monaco; S Ferrari Journal: J Neurol Date: 2015-04-01 Impact factor: 4.849
Authors: Howard A Crystal; Jeremy Weedon; Susan Holman; Jennifer Manly; Victor Valcour; Mardge Cohen; Kathryn Anastos; Chenglong Liu; Wendy J Mack; Elizabeth Golub; Jason Lazar; Ann Ho; Mary Jeanne Kreek; Robert C Kaplan Journal: J Neurovirol Date: 2011-10-18 Impact factor: 2.643
Authors: Robert C Kalayjian; Kevin R Robertson; Jeffrey M Albert; Carl J Fichtenbaum; Todd T Brown; Babafemi O Taiwo Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: James T Becker; Lawrence A Kingsley; Samantha Molsberry; Sandra Reynolds; Aaron Aronow; Andrew J Levine; Eileen Martin; Eric N Miller; Cynthia A Munro; Ann Ragin; Ned Sacktor; Ola A Selnes Journal: Int J Epidemiol Date: 2014-04-24 Impact factor: 7.196